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Abstract
Background: Development of multiple primary tumors is a hallmark of hereditary cancer. At least
1/10 of breast cancers and colorectal cancers occur because of heredity and recently the cell cycle
kinase 2, CHEK2 1100delC allele has been identified at a particularly high frequency in families with
hereditary breast and colorectal cancer.
Methods: We utilized the Southern Sweden population-based cancer registry to identify women
with double primary breast and colorectal cancer and sequenced tumor material in order to assess
the contribution of the CHEK2 1100delC to the development of such metachronous tumors.
Results: Among the 75 patients successfully analyzed, 2 (2.5%) carried the CHEK2 1100delC allele.
which was not significantly different (p = 0.26) from the 1% (3/300) carriers identified in the control
group.
Conclusion: In summary, our data suggest that the CHEK2 1100delC is not a major cause of
double primary breast and colorectal cancer in Sweden, which suggests that this patient group
should not routinely be screened for the CHEK2 1100delC variant.
Background
At least 10% of both breast cancers and colorectal cancers
are estimated to develop because of heredity. The BRCA1
and BRCA2 genes are the major causes of hereditary breast
and ovarian cancer, but the underlying genetic defect
remains unresolved in the majority of the families with
familial or hereditary breast cancer [1,2]. In colorectal
cancer, familial adenomatous polyposis due to mutations
in APC and the hereditary nonpolyposis colorectal cancer
(HNPCC) syndrome caused by mutations in the mis-
match-repair genes MLH1, MSH2, MSH6 and PMS2 are
the underlying causes of many families with hereditary
colorectal, whereas the genetic defects remains unknown
in most of the families with hereditary colorectal cancer
with higher age at onset and lack of other associated
tumor types [3,4]. Searches for additional high-penetrant
disease-causing genes in these cancer types have so far not
been successful and it is likely that low-penetrant genetic
variants may contribute a substantial fraction of heredi-
tary breast cancer and colorectal cancer [3,5].
Double-strand DNA breaks lead to activation of the cell
cycle checkpoint kinase 2, CHEK2 [GenBank:AL121825],
through ATM phosphorylation [6]. CHEK2 plays an
important role in cell cycle regulation and DNA damage
repair, processes that are central in prevention of tumor
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development. The CHEK2 1100delC mutation leads to
premature termination and abrogates kinase activity. This
variant allele occurs in about 1% of normal populations,
but has been identified at increased frequencies (1.2–
1.9%) in individuals with breast cancer [7,8]. An approx-
imately 2-fold increased risk of breast cancer has been
associated with the CHEK2  1100delC mutation [8].
Higher frequencies, 5.1–11.4%, of the CHEK2 1100delC
allele have by some investigators been reported in non-
BRCA1/2  families with hereditary breast cancer [8-11],
although other studies from e.g. Australia and Spain have
not found an increased frequency in such families
[12,13]. These differences may be ascribed to geographical
variations as well as to different sample sets, particularly
regarding the number of family members affected, age at
onset, and selection of e.g. families with male breast can-
cer. Since the CHEK2 1100delC variant does not show
clear co-segregation with disease it is considered to be a
modifier, and may act in cooperation with yet unidenti-
fied high-penetrance genes or together with multiple low-
penetrant genes as part of polygenic inheritance.
In studies from Finland and the Netherlands the CHEK2
1100delC has been reported at frequencies of 1.6–2.6%
among individuals with colorectal cancer, which is not
significantly higher than in unaffected individuals from
the population, but these studies may be compatible with
a risk of 1.5–2.0 for development of colorectal cancer
among carriers [14-16]. A particularly high frequency of
the CHEK2 1100delC allele has been reported in families
with hereditary breast and colorectal cancer where 10/55
Dutch families (18%) carried the mutation [16].
Since development of multiple primary tumors in an indi-
vidual is a sign of hereditary cancer we utilized a popula-
tion-based cancer registry to identify women who had
developed breast cancer and colorectal cancer in order to
assess the contribution of the CHEK2 1100delC mutation
to the development of metachronous cancers of these
types.
Methods
Patient material
Ethical approval was obtained from the ethics committee
at the Lund University. We utilized the population-based
cancer registry of the Southern swedish health care region
(which currently has approximately 1.7 million inhabit-
ants). The registry was established in 1958 and because of
mandatory cancer registration for clinicians as well as for
pathologists the registry is estimated to contain 98% of all
cancers diagnosed in this area. All females diagnosed with
at least one breast cancer and one colorectal cancer during
the time period 1958–2000 were identified. Totally 96
patients were identified in whom breast cancer was the
first tumor in 64 and colorectal cancer was the first tumor
in 25, whereas the remaining 7 patients developed syn-
chronous breast and colorectal cancer. The mean age at
diagnosis of the first of tumor was 68 (range 40–95) years,
breast cancer developed at mean age 70 (range 40–95)
and colorectal cancer at age 74 (range 47–98). After omis-
sion of patients who were misclassified or from whom the
tumor blocks could not be retrieved, 84 patients remained
for analysis.
Tumor-containing paraffin-embedded tissue and normal
tissue (e.g. resection borders or benign lymph nodes)
were retrieved. Fresh sections were obtained and stained
with Hematoxylin & Erythrosin in order to verify that
tumor tissue was present in the samples. DNA was
extracted from 3 × 10 μm paraffin sections using treat-
ment with Proteinase K in 65°C for at least 2 hours and
boiled for 10 minutes for enzyme inactivation, whereafter
the samples were centrifuged and the aqueous phase was
removed for use.
dHPLC and sequencing
Mutation analysis was carried out using dHPLC (Transge-
nomic WAVE Nucleic Acid Fragment Analyzer System
Model 3500HT) and samples with aberrant patterns were
further analyzed by direct sequencing (Terminator Cycle
Sequencing Reaction Kits version 3.1, ABI Prism 3100
Genetic Analyzer; Applied Biosystems). Due to homolo-
gous sequences primer design is complex for CHEK2 exon
10. The primers used were 5'-TGGCAAGTTCAACATTAT-
TCCC-3' (forward) [17] and 5'-ATCACCTCCTAC-
CAGTCTGTGC-3' (reverse) [10]. PCR amplification was
performed in a final volume of 25 μl containing: 2.5 μl 10
× PCR buffer, 2–3 μl MgCl (25 mM), 0.5 μl dNTP (20
mM), 0.7 μl primer (10 μM) and 0.1 μl polymerase. PCR
conditions are available from the authors upon request.
Heteroduplex formation was performed by mixing tumor
DNA with wild-type DNA, heating to 94°C and lowering
the temperature by 1°C per minute until 45°C was
reached.
Results
Of the 84 patients, 75 (89%) were successfully analyzed.
In total, 36 breast cancers and 67 colorectal cancers were
analyzed and from 34 patients normal tissue was also ana-
lyzed. The majority of the patients developed breast can-
cer as their first tumor (table 1) and 68 of the patients
developed other malignant tumors, most commonly
malignant melanoma (n = 18), endometrial cancer (n =
12) and urinary bladder cancer (n = 6). The CHEK2
1100delC mutation was detected in 2 patients (2.5%)
(table 2). Both the breast cancer and the colorectal cancer
was analyzed and found to carry the mutation in these
cases and, in case 17 the mutation was verified also in nor-
mal tissue. Chromatograms over the results are shown in
figure 1.BMC Cancer 2006, 6:64 http://www.biomedcentral.com/1471-2407/6/64
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In order to determine the expected frequency of the
CHEK2 1100delC in the Southern swedish population
dHPLC analysis and direct sequencing was performed
from 300 healthy individuals with identification of the
variant allele in 3/300 individuals, thus at a population
frequency of 1% [18].
Discussion
A subtype of familial breast cancer that includes colorectal
cancer was recognized by Lynch et al. already in 1972 [19]
and recently the CHEK2  1100delC mutation was pro-
posed to represent a low-penetrant breast cancer suscepti-
bility allele [10,11]. This variant has been identified at a
particularly high frequency (18%) in families with a
hereditary breast- and colorectal cancer phenotype [16].
Since development of multiple primary tumors is a hall-
mark of hereditary cancer and a high frequency of the
CHEK2 1100delC had been described in hereditary breast
and colorectal families, we assessed the contribution of
this variant to the development of double primary breast
and colorectal cancer in a population-based patient mate-
rial. Among the 75 patients with metachronous tumors of
the breast and the colorectum successfully studied, 2
(2.5%) carried the CHEK2 1100delC mutation compared
to 1% in the control group [18]. These frequencies were
not significantly different (p = 0.26), but the small size of
the population-based patient material limits the strength
of this comparison. However, the low frequency of this
alteration in our material implies that development of
metachronous breast cancer and colorectal cancer in
women is per se not alone to identify individuals with a
high likelihood of being carriers of the CHEK2 1100delC
mutation. Although development of double primary
tumors may be a sign of heredity it is not enough to rec-
ommend genetic analysis, though the family history of
cancer should be carefully reviewed. Our findings are in
line with previous studies that exclude CHEK2 1100delC
as a major contributor to the breast and colorectal cancer
phenotype [16]. Huang et al. [20] did not identify any
CHEK2 1100delC mutation among 24 patients from the
US with breast cancer and colorectal cancer. Also, in the
study by Meijers-Heijboer et al. that primarily identified
the link between CHEK2 1100delC and familial breast
and colorectal cancer in Dutch families, the vast majority,
45/55 families, who fulfilled these criteria did indeed not
carry this variant [16]. However geographical differences
may influence the importance of the CHEK  1100delC
mutation.
Among the two women with the CHEK2 1100delC allele
in our study, one presented with two separate, synchro-
nous, breast cancers. An increased risk of multiple primary
dHPLC and reverse sequence results that demonstrate the  CHEK2 1100delC variant in the two patients Figure 1
dHPLC and reverse sequence results that demonstrate the 
CHEK2 1100delC variant in the two patients. Both patients 
were heterozygous mutation carriers. The heteroduplex for-
mations are seen as extra peaks in the dHPLC chromato-
gram.
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Table 1: Clinical data in the cohort analyzed (n = 75).
Tumor type Mean age (range) at diagnosis (years)
Breast cancer 70 (40–94)
Colorectal cancer 74 (47–92)
Age at first cancer 68 (40–90)
Breast cancer as first cancer (n = 50) 68 (40–93)
Colorectal cancer as first cancer (n = 20) 70 (48–85)
Synchronous breast and colorectal cancer (n = 5) 70 (47–82)
Table 2: Clinical data from the two individuals carrying the 
CHEK2 1100delC mutation.
Patient Cancer type Age (years)
B17 Rectal cancer 69
Renal cancer 73
Breast cancer 74
B79 Synchronous breast cancer 47
Colon cancer 48
Renal cancer 49BMC Cancer 2006, 6:64 http://www.biomedcentral.com/1471-2407/6/64
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breast cancers (OR 5.7–6.5) has been reported in individ-
uals carrying this CHEK2  1100delC allele [11,21,22].
However, the CHEK2 1100delC mutation has not only
been suggested to act as a low-penetrant susceptibility
gene in breast cancer families, but the CHEK2 I157T alter-
ation has been proposed to act as a multiorgan cancer sus-
ceptibility allele based on observations of an increased
risk for development of breast cancer, colon cancer, pros-
tate cancer, thyroid cancer, and renal cancer in Polish fam-
ilies [23]. Both patients in our study, did in addition to
breast cancer and colorectal cancer, develop a third tumor,
two renal cancers at ages 49 and 73 (table 2). In the Swed-
ish cancer registry 8–10% of the patients develop 2 or
more malignancies (The Board of Social Health and Wel-
fare, Cancer Incidence in Sweden 2003). The develop-
ment of renal cancer in two of our patients was intriguing
in relation to Cybulski et al. who identified an increased
risk of renal cancer associated with CHEK2, albeit in carri-
ers of the CHEK2 I157T variant [23]. However, since our
study was registry-based no data on additional cancer
cases in these families are available.
Conclusion
In summary, our findings demonstrate that the CHEK2
1100delC occurs at a low frequency in Swedish women
with double primary breast cancer and colorectal cancer,
and thus suggests that development of these two tumor
types is not sufficient to recommend mutation analysis of
CHEK2.
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